Compare FPF & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | BLFS |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 1989 |
| Metric | FPF | BLFS |
|---|---|---|
| Price | $18.67 | $25.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 186.7K | ★ 334.7K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,144,000.00 |
| Revenue This Year | N/A | $20.67 |
| Revenue Next Year | N/A | $14.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $13.91 | $19.10 |
| 52 Week High | $18.09 | $29.62 |
| Indicator | FPF | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 50.82 |
| Support Level | $18.60 | $23.58 |
| Resistance Level | $18.75 | $25.63 |
| Average True Range (ATR) | 0.13 | 0.88 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 59.09 | 57.26 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.